MXCT
MaxCyte, Inc. (NASDAQ)
Healthcare — Medical Devices
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. The company has strategic partnership with VectorBuilder focused on co-developing a new gene delivery solution. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
Price History
Fundamentals
| Market Cap | $131.76M |
| P/E Ratio (TTM) | - |
| Forward P/E | -4.94 |
| EPS (TTM) | $-0.36 |
| Dividend Yield | - |
| Profit Margin | -121.16% |
| Revenue Growth | -7.10% |
| ROE | -21.30% |
| Debt/Equity | 10.42 |
| Recommendation | None |
| Analyst Target | $4.11 |
| Analysts | 4 |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 60.3 |
| Beta | 1.67 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $2.37 |
| 52-Week Low | $0.64 |
| 50-Day Avg | $1.05 |
| 200-Day Avg | $1.20 |
| Avg Volume | $1.15M |
| Volume | 482.4K |
Performance Analysis
NEUTRALMXCT presents a mixed picture with both positive and negative indicators.
Recent News
Last updated: Jul 02, 2026 13:21 UTC
Back to Screener Export Report